Used in research and therapeutic development targeting the complement system, particularly the alternative pathway. This antibody specifically binds to Complement Factor P (Properdin), stabilizing the C3 and C5 convertases and enhancing complement activation. By neutralizing Properdin, it enables precise modulation of excessive complement activity associated with inflammatory and autoimmune diseases such as atypical hemolytic uremic syndrome (aHUS), paroxysmal nocturnal hemoglobinuria (PNH), ischemia-reperfusion injury, and certain kidney diseases. Its high specificity makes it valuable in diagnostic assays to detect Properdin levels in biological samples and in preclinical models to study complement-mediated tissue damage. Due to its role in controlling unregulated complement activation, it is being explored as a potential biologic for treating conditions where complement overactivation leads to pathology.